13F Holdings
中文EN

CNTB Connect Biopharma Holdings Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835268 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY382.0%
TTM net income YoY-37.9%
TTM EPS YoY-28.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,879.9%
Net margin-1,849.7%
FCF margin-1,504.2%
EBITDA margin-1,861.7%

Returns

ROE-201.5%
ROA-142.8%
ROIC (approx.)-834.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets56.6%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · USDFY20212021-12-31 · CNY
Income statement
Revenue$64,000$26.03M$0——
R&D expense$37.80M$29.26M$53.00M$96.63M518.02M
SG&A expense$20.34M$19.23M$16.05M——
Operating income-$58.07M-$22.45M-$69.06M-$119.32M-631.44M
Interest expense——$23,000$21,000114,000
Pretax income-$55.28M-$15.40M-$61.99M-$117.79M-1.31B
Income tax$197,000$223,000$120,000$298,0001.70M
Net income-$55.48M-$15.63M-$62.11M-$118.09M-1.31B
EBITDA-$57.37M-$21.79M-$68.34M-$118.28M-627.35M
EPS (basic)-1.00-0.28-1.13-2.15-25.00
EPS (diluted)-1.00-0.28-1.13-2.15-25.00
Weighted avg. shares (diluted)55.66M55.21M55.07M——
Balance sheet
Cash & equivalents$38.34M$78.23M$105.66M$78.95M1.71B
Short-term investments$6.00M$15.48M$12.64M——
Receivables$13,000$789,000$0——
Current assets$50.93M$96.96M$122.55M$155.78M1.75B
PP&E, net$3.81M$4.05M$4.27M$4.98M59.34M
Intangibles$45,000$53,000$62,000——
Total assets$56.08M$101.28M$127.38M$174.01M1.86B
Current liabilities$13.61M$8.46M$25.29M$15.62M114.67M
Total liabilities$14.10M$9.12M$25.88M$16.52M119.83M
Shareholders' equity$41.98M$92.17M$101.50M$158.42M1.74B
Shares outstanding56.44M55.35M55.10M55.04M55.08M
Cash flow statement
Operating cash flow-$51.21M-$23.61M-$47.74M-$101.52M-544.93M
Capital expenditure$434,000$750,000$81,000$4.41M24.94M
Free cash flow-$51.64M-$24.36M-$47.82M-$105.92M-569.87M
Investing cash flow$9.82M-$3.45M$74.98M-$86.24M-34.02M
Financing cash flow$1.09M$227,000$45,000-$85,0001.32B
Depreciation & amortization$704,000$660,000$720,000$1.03M4.08M
Stock-based compensation$3.73M$6.73M$5.40M$6.91M57.86M
Share buybacks——$0$03.67M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.